Search
for
Sort by
Research
210-240 / 1000+ resultsresearch 022 Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopeciaareata in pre-clinical models
The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
research Antiandrogenic activity of Riboflavin 5′-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines
Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
research 599 PPARg signaling modulation protects from hair follicle bulge stem cell damage and cyclophosphamide-induced hair follicle cytotoxicity
PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.
research Secreted Frizzled-related protein 4 inhibits the regeneration of hair follicles
A protein called sFRP4 can slow down hair regrowth.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research The epidermal growth factor receptor decreases S tathmin 1 and triggers catagen entry in the mouse
EGFR helps mouse hair follicles stop growing by reducing certain growth regulators.
research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth? - eScholarship
Manipulating EGFR signaling may help treat hair loss and promote hair growth.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Systemic tofacitinib in paediatric alopecia areata
research Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
The cream effectively and safely reduces facial hair in women.
research Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts
Alternating treatment with two drugs could help cells in a rapid aging disease.
research O04 HPV8 E6 leads to Lrig1+ keratinocyte stem cell expansion
HPV8 E6 gene causes growth of certain skin stem cells.
research Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
research EBF1 expressed in the dermal papilla regulates hair type and length
EBF1 controls hair type and length.
research 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
research Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
research Specific Inhibition of Hair Follicle Formation by Epidermal Growth Factor in an Organ Culture of Developing Mouse Skin
research Hypaphorine, an indole-3-acetic acid antagonist delivered by the ectomycorrhizal fungus Pisolithus tinctorius , induces reorganisation of actin and the microtubule cytoskeleton in Eucalyptus globulus ssp bicostata root hairs
Hypaphorine from a fungus changes the internal structure of Eucalyptus root hairs, stopping their growth.
research 1311 Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia
Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.